Company profilePharmaceutical#667 of 1,318 in Pakistan2 DRAP alerts

IBL HEALTH CARE (PVT) LTD

Pharmaceutical company · 15 brands · 11 molecules

Ranked #11 of 12 companies in Immune Sera And Immunoglobulins

15 registered products 10 pharmaceutical brands 11 distinct molecules 2 DRAP alerts

Company overview

15
registered products
10
pharmaceutical brands
11
distinct molecules
1
therapeutic classes
2
DRAP alerts

IBL HEALTH CARE (PVT) LTD is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 15 product registrations across 11 distinct molecules. Its portfolio is concentrated in Immune Sera And Immunoglobulins. DRAP has issued 2 alerts involving its products.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by IBL

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Immune Sera And Immunoglobulins 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

1
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
20261

Top molecules by brand count

Therapeutic classes

Immune Sera And Immunoglobulins · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official1 products · Rs 11,380.64 – Rs 11,380.64
Median across source: Rs 11,380.64

Regulatory record

2 alerts in the DRAP feed we track.

10. Rapid Alert – Spurious Injection RHOPHYLAC 300 µg (Batch # P100707423)
2026-03-11
Rapid Alert: PRESENCE OF FALSIFIED INJECTION RHOPHYLAC 300MCG, HUMAN ANTI-D IMMUNOGLOBULIN
2025-04-30

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

HAKIMSONS IMPEX (PVT) LTD. holds 9 molecules not in this portfolio
Anti D ImmunoglobulinAnti-D ImmunoglobulinBicalutamideCapecitabineDocetaxelGemcitabine
SANOFI AVENTIS (PAKISTAN) LTD. holds 76 molecules not in this portfolio
AlfuzosinAmilorideAmiodaroneAspirinAtorvastatinBacillus Clausii
SIND MEDICAL STORES holds 5 molecules not in this portfolio
CaliforniaHepatitis A VaccineHepatitis A Virus AntigenInfluenza VaccineNymc X-179A Reassortant Derived From A

Get the full profile for IBL

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.